Clinical trial
An Open-Label Biomarker Study of BHV-1400 in IgA Nephropathy
NCT07054684 is registered in ClinicalTrials.gov with Biohaven Therapeutics Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label Biomarker Study of BHV-1400 in IgA Nephropathy
- Lead sponsor
- Biohaven Therapeutics Ltd.
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- July 30, 2025
- Completion date
- July 31, 2027
- Enrollment
- 20 (estimated)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.
iga nephropathy